SHANGHAI, May 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the...
Read More Details
Finally We wish PressBee provided you with enough information of ( ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) )
Also on site :
- Iconic Sitcom Actress, 67, Stuns With Ageless Appearance 20 Years After Show Ended
- Nazi symbols prevalent in Ukrainian military – Le Monde
- Beloved ‘90s Icon Meets Iconic ‘Pitch Perfect’ Stars in an Unforgettable Red Carpet Moment